ABCL logo

ABCL
AbCellera Biologics Inc

8,304
Mkt Cap
$1.19B
Volume
3.84M
52W High
$6.52
52W Low
$1.94
PE Ratio
-7.97
ABCL Fundamentals
Price
$3.99
Prev Close
$3.91
Open
$3.92
50D MA
$3.44
Beta
1.50
Avg. Volume
2.69M
EPS (Annual)
-$0.4901
P/B
1.22
Rev/Employee
$133,679.71
$604.47
Loading...
Loading...
News
all
press releases
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
AbCellera (Nasdaq: ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Upgraded to "Strong-Buy" at JonesTrading
JonesTrading raised shares of AbCellera Biologics to a "strong-buy" rating in a research note on Thursday...
MarketBeat·10d ago
News Placeholder
JonesTrading Begins Coverage on AbCellera Biologics (NASDAQ:ABCL)
JonesTrading initiated coverage on shares of AbCellera Biologics in a research note on Friday. They issued a "buy" rating and a $11.00 target price for the company...
MarketBeat·11d ago
News Placeholder
Tudor Investment Corp ET AL Invests $3.67 Million in AbCellera Biologics Inc. $ABCL
Tudor Investment Corp ET AL bought a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the third quarter, according to the company in its most recent 13F filing with...
MarketBeat·11d ago
News Placeholder
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
AbCellera (Nasdaq: ABCL) will announce its first quarter 2026 financial results on Monday, May 11, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the...
Business Wire·20d ago
News Placeholder
AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum
AbCellera Biologics (NASDAQ:ABCL) is working to evolve from a technology-enabled drug discovery partner into what the company described as an integrated biotech with internal programs advancing through mid- to late-stage development, according to comments from Senior Director of Strategic Finance an...
MarketBeat·1mo ago
News Placeholder
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says
AbCellera Biologics (NASDAQ:ABCL) is positioning itself as a more pipeline-driven biotechnology company after more than a decade of platform investment, according to comments from Senior Director of...
MarketBeat·2mo ago
News Placeholder
DNB Asset Management AS Buys Shares of 656,208 AbCellera Biologics Inc. $ABCL
DNB Asset Management AS purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the third quarter, according to the company in its most recent disclosure with...
MarketBeat·2mo ago
News Placeholder
What Sparked AbCellera Biologics To Soar Over 9% After Hours
AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.read more...
Benzinga·2mo ago
News Placeholder
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +83.56% and +565.48%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
<
1
2
...
>

Latest ABCL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.